Schmidt K - Search Results

1

Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.

Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, Duchrow M, Wohlschläger C, Feller AC, Stange EF. Wehkamp J, et al. Among authors: schmidt k. Eur J Gastroenterol Hepatol. 2002 Jul;14(7):745-52. doi: 10.1097/00042737-200207000-00006. Eur J Gastroenterol Hepatol. 2002. PMID: 12169983

2

Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment.

Schröder T, Schmidt KJ, Olsen V, Möller S, Mackenroth T, Sina C, Lehnert H, Fellermann K, Büning J. Schröder T, et al. Among authors: schmidt kj. Eur J Gastroenterol Hepatol. 2015 Jun;27(6):698-704. doi: 10.1097/MEG.0000000000000350. Eur J Gastroenterol Hepatol. 2015. PMID: 25923946

3

Crohn's targeted therapy: myth or real goal?

Schmidt KJ, Büning J, Jankowiak C, Lehnert H, Fellermann K. Schmidt KJ, et al. Curr Drug Discov Technol. 2009 Dec;6(4):290-8. doi: 10.2174/157016309789869083. Curr Drug Discov Technol. 2009. PMID: 20025597

4

Cyclophosphamide therapy in Sweet's syndrome complicating refractory Crohn's disease − Efficacy and mechanism of action.

Meinhardt C, Büning J, Fellermann K, Lehnert H, Schmidt KJ. Meinhardt C, et al. Among authors: schmidt kj. J Crohns Colitis. 2011 Dec;5(6):633-7. doi: 10.1016/j.crohns.2011.07.014. Epub 2011 Aug 27. J Crohns Colitis. 2011. PMID: 22115387

5

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues.

Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Büning J. Schmidt KJ, et al. J Crohns Colitis. 2016 Jan;10(1):31-7. doi: 10.1093/ecco-jcc/jjv175. Epub 2015 Sep 28. J Crohns Colitis. 2016. PMID: 26419459

6

Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.

Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Schmidt KJ, et al. Aliment Pharmacol Ther. 2013 Jan;37(1):129-36. doi: 10.1111/apt.12118. Epub 2012 Nov 5. Aliment Pharmacol Ther. 2013. PMID: 23121200

7

Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn's disease.

Schmidt KJ, Fellermann K, Wellhöner P, Weitz G, Homann N, Herrlinger K, Lehnert H, Ludwig D, Büning J. Schmidt KJ, et al. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1230-9. doi: 10.1111/j.1365-2036.2009.03999.x. Epub 2009 Mar 19. Aliment Pharmacol Ther. 2009. PMID: 19302074 Clinical Trial.

8

Detrimental effect of high volume fluid administration in acute pancreatitis - a retrospective analysis of 391 patients.

Weitz G, Woitalla J, Wellhöner P, Schmidt K, Büning J, Fellermann K. Weitz G, et al. Among authors: schmidt k. Pancreatology. 2014 Nov-Dec;14(6):478-83. doi: 10.1016/j.pan.2014.07.016. Epub 2014 Oct 12. Pancreatology. 2014. PMID: 25451185

9

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus.

Herrlinger KR, Barthel DN, Schmidt KJ, Büning J, Barthel CS, Wehkamp J, Stange EF, Fellermann K. Herrlinger KR, et al. Among authors: schmidt kj. Aliment Pharmacol Ther. 2010 May;31(9):1036-41. doi: 10.1111/j.1365-2036.2010.04267.x. Epub 2010 Feb 18. Aliment Pharmacol Ther. 2010. PMID: 20175769

10

Does etiology of acute pancreatitis matter? A review of 391 consecutive episodes.

Weitz G, Woitalla J, Wellhöner P, Schmidt K, Büning J, Fellermann K. Weitz G, et al. Among authors: schmidt k. JOP. 2015 Mar 20;16(2):171-5. doi: 10.6092/1590-8577/2959. JOP. 2015. PMID: 25791551

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results